DT

Degrome Therapeutics at TPD Summit 2026

Oct 26–29, 2026 Boston, MA ~300 attendees Website

Degrome Therapeutics takes part in 2 sessions at TPD Summit 2026 in Boston. Its talks present molecular glue degraders in two settings, removing mutant KRAS together with CRAF in tumor models and boosting lysosomal clearance of APP to reduce amyloid in Alzheimer's disease.

OrganizationTPD Summit 2026 Attendance
DT
Degrome Therapeutics
Biotech
Indiana biotech discovering small-molecule degraders of proteins that cause neurodegenerative disease, starting from an APP degrader.
Talk
Wed Oct 28
4:15pm
Molecular Glue Degrader–Induced Co-Degradation of Mutant KRAS & CRAF Drives In Vivo Responses
Plenary
Degrader discovery & design
Talk
Thu Oct 29
2:15pm
Molecular Glue Degraders Enhance CAPRIN1-Dependent Lysosomal Degradation of APP & Reduce Amyloid in Alzheimer’s Disease
Future of Induced Proximity Track
Degrader discovery & design

Explore the full TPD Summit 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full TPD Summit 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Degrome Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction